Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements

Aim The primary objective of this study was to evaluate the prevalence of increased controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) as surrogate markers of liver steatosis and fibrosis in liver transplant recipient (LTR). Secondary objectives were to determine the predictors of increased CAP and LSM in population of LTR. Methods In this prospective, cross-sectional study, we have evaluated 175 LTRs' mean age as 61 (53–65) with a functioning graft for more than one year who came for regular outpatient examinations to the Department of Gastroenterology, University Hospital (UH) Merkur, Zagreb, Croatia. Results Of 175 analyzed LTRs, 34.28% had obesity, 64.00% had hypertension, 38.28% had diabetes, and 58.85% had hyperlipidemia. The prevalence of liver steatosis was 68.57%, while the prevalence of severe liver steatosis was 46.85%. On multivariate analysis, independent factors associated with liver steatosis were male gender, total cholesterol as positive predictor, and HDL as negative predictor, and independent factors positively associated with severe liver steatosis were higher body mass index (BMI) and higher triglyceride levels. The prevalence of moderate liver fibrosis was 54.85%, while the prevalence of advanced liver fibrosis was 24%. On multivariate analysis, independent factors positively associated with moderate fibrosis were gamma-glutamyl transferase (GGT) and CAP, while the independent factor positively associated with advanced fibrosis was GGT. Conclusion Our study showed high prevalence of increased CAP and LSM measurements as surrogate markers of liver steatosis and fibrosis. Metabolic syndrome components were highly present and were associated with CAP and LSM values as well as in the pretransplant setting. Due to high prevalence of metabolic comorbidities and nonalcoholic fatty liver disease in LTRs and the lack of the abnormal liver test in a significant number of these patients, TE with CAP may be a reasonable initial assessment for LTRs with one or more components of the metabolic syndrome.

[1]  A. Mijić,et al.  Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. , 2020, European journal of internal medicine.

[2]  T. Schiano,et al.  The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. , 2020, Transplantation proceedings.

[3]  T. Bokun,et al.  Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. , 2019, Journal of diabetes and its complications.

[4]  T. Schiano,et al.  A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post–liver transplant patient , 2019, Clinical transplantation.

[5]  M. Allison,et al.  Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[6]  A. Allen,et al.  Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation , 2019, Transplantation.

[7]  W. Hager,et al.  and s , 2019, Shallow Water Hydraulics.

[8]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[9]  S. Gitto,et al.  De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients , 2018, European journal of gastroenterology & hepatology.

[10]  I. Mikolasevic,et al.  Fatty liver allografts are associated with primary graft non‐function and high mortality after transplantation , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[11]  D. S̆timac,et al.  Nonalcoholic fatty liver disease - A multisystem disease? , 2016, World journal of gastroenterology.

[12]  G. Targher,et al.  Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. , 2016, Journal of diabetes and its complications.

[13]  D. S̆timac,et al.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? , 2016, World journal of gastroenterology.

[14]  L. Orlić,et al.  Metabolic syndrome and non‐alcoholic fatty liver disease after liver or kidney transplantation , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[16]  D. S̆timac,et al.  Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done? , 2015, World journal of gastroenterology.

[17]  T. Berg,et al.  Noninvasive characterization of graft steatosis after liver transplantation , 2015, Scandinavian journal of gastroenterology.

[18]  J. Dumortier,et al.  Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  L. Orlić,et al.  Non-Alcoholic Fatty Liver Disease Proven by Transient Elastography in Hemodialysis Patients: Is It a New Risk Factor for Adverse Cardiovascular Events? , 2014, Blood Purification.

[20]  L. Orlić,et al.  Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography. , 2014, Transplantation proceedings.

[21]  Y. Choi,et al.  Histologically proven non‐alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation , 2014, Clinical transplantation.

[22]  D. S̆timac,et al.  Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease , 2014, Wiener klinische Wochenschrift.

[23]  G. Hauser,et al.  Hitna medicina ili medicina za sve , 2013 .

[24]  D. S̆timac,et al.  Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease Proven by Transient Elastography , 2013, Kidney and Blood Pressure Research.

[25]  V. Wong,et al.  Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.

[26]  W. Marsden I and J , 2012 .

[27]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.

[29]  L. Rubbia‐Brandt,et al.  Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil” , 2010, American Journal of Gastroenterology.

[30]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[31]  A. McCullough,et al.  Posttransplant metabolic syndrome: An epidemic waiting to happen , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  G. Marchesini,et al.  Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  A. Diehl,et al.  De Novo nonalcoholic fatty liver disease after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.